Yokukansan improves distress of medical staff, and cognitive function and motivation in patients with destructive and aggressive behaviors after traumatic brain injury

• Published in: Acute medicine & surgery Vol. 1; no. 2; pp. 88 - 93
• Main Authors: Kan'o, Tomomichi, Han, Jing‐Yan, Nakahara, Kuniaki, Konno, Shingo, Shibata, Mayuko, Kitahara, Takao, Soma, Kazui
• Format: Journal Article
• Language: English
• Published: United States John Wiley and Sons Inc 01-04-2014
• Subjects: Cognitive function; destructive and aggressive behaviors; drug interactions; Original; traumatic brain injury; yokukansan; traumatic brain injury; destructive and aggressive behaviors; yokukansan; drug interactions; Cognitive function
• ISSN: 2052-8817; 2052-8817
• DOI: 10.1002/ams2.24

Aim
Yokukansan (a Japanese Kampo medicine) has been reported to be safe and useful in treating behavioral and psychological symptoms in dementia patients. This study aimed to investigate the effects of yokukansan on destructive and aggressive behaviors in patients after traumatic brain injury.
Methods
From April 2008 to July 2010, 189 patients who suffered traumatic brain injury were admitted to our tertiary emergency center. Of these, patients with destructive and aggressive behaviors were treated with neuroleptics. Seven patients (five men and two women) who could not be controlled by neuroleptics were given yokukansan (2.5 g powder) three times a day before meals. Main underlying conditions included brain contusion in three patients, acute subdural hematoma in two, and acute epidural hematoma in two. The following assessments were carried out at baseline and 1 and 2 weeks after initiation of treatment: the Glasgow Coma Scale for the assessment of disturbed consciousness after traumatic brain injury; Neuropsychiatric Inventory for the distress of medical staff; Mini‐Mental State Examination for cognitive function; Barthel Index for activities of daily living; Vitality Index for motivation; presence of adverse effects and drug interactions.
Results
After treatment with yokukansan, patients showed significant improvements in Glasgow Coma Scale (P = 0.001), Neuropsychiatric Inventory (P = 0.016), Mini‐Mental State Examination (P = 0.029), Barthel Index (P = 0.043), and Vitality Index (P = 0.013). No adverse effects or drug interactions between yokukansan and Western medicines were observed.
Conclusion
Yokukansan improved the Glasgow Coma Scale, Neuropsychiatric Inventory, Mini‐Mental State Examination, Barthel Index, and Vitality Index without any adverse effects or drug interactions with Western medicines in patients with destructive and aggressive behaviors after traumatic brain injury.